The "Transfection Reagents and Equipment - Global Strategic Business Report" has been added tAndMarkets.com's offering.The ...
Researchers have deployed a method for mitochondrial transfer to overcome T-cell exhaustion during treatment of solid tumors.
Enter MaxCyte, which has been developing and optimizing its Flow Electroporation® technology, allowing cells to move through ...
AZoLifeSciences on MSN1d
Modified Nucleotides Boost saRNA Vaccine Efficacy and Protection Against SARS-CoV-2Modified nucleotides like m5C in saRNA enhance vaccine efficacy, stability, and reduce inflammation, offering a promising ...
Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...
News Medical on MSN1d
Asimov Launches AAV Edge, a Suite of AI Models, Host Cells, and Genetic Tools for End-to-End Gene Therapy DevelopmentAsimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the ...
The choice of scaling strategy—“up,” “out,” or “down”—depends on a biomanufacturer’s business strategy and product demand ...
GlobalData on MSN2d
MaxCyte and Kamau Therapeutics sign platform license agreementKamau Therapeutics will gain non-exclusive research, clinical and commercial rights to utilise MaxCyte's Flow Electroporation ...
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, ...
However, whether BCAS2 has other functions within the nucleus remains largely unknown. Here, we show that BCAS2 is essential for primitive hematopoiesis in zebrafish and mouse embryos. The activation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback